J Korean Med Sci.  2012 Dec;27(12):1524-1529. 10.3346/jkms.2012.27.12.1524.

Comparison of Lipid-Related Ratios for Prediction of Chronic Kidney Disease Stage 3 or More in Korean Adults

• Kim JY
• Kang HT
• Lee HR
• Lee YJ
• Shim JY

• KMID: 2157976
• DOI: http://doi.org/10.3346/jkms.2012.27.12.1524

Abstract

Dyslipidemia is implicated in increased cardiovascular risk associated with chronic kidney disease (CKD) and in the progression of renal damage. This study compared 4 different lipid-related ratios (total cholesterol [TC]/high-density lipoprotein cholesterol [HDL-C], triglyceride [TG]/HDL-C, calculated low-density lipoprotein cholesterol [c-LDL-C]/HDL-C, and non-HDL-C/HDL-C ratio) for prediction of CKD stage 3 or more to investigate the association between them. This cross-sectional study included 8,650 adults who participated in the 2007-2008 Korean National Health and Nutrition Examination Survey. The overall prevalence of CKD stage 3 or more was 6.4%. For TG/HDL-C, the prevalence with CKD stage 3 or more increased with increasing quartile group in both sexes (P value for trend = 0.046 in men, 0.002 in women) while other lipid-related ratios showed increasing prevalence only in women. In comparison with the lowest quartile of the lipid-related ratios, only the fourth quartile of TG/HDL-C was associated with the prevalence of CKD stage 3 or more in both sexes after adjustment for multiple covariates (odds ratio [OR] for TG/HDL-C-Q4, 1.82; 95% CI [confidence interval], 1.09-3.03 in men, OR 2.45; 95% CI, 1.52-3.95 in women). In conclusion, TG/HDL-C is the only lipid-related ratio that is independently associated with CKD stage 3 or more in both sexes of Koreans.

Keyword

Kidney Failure, Chronic; Dyslipidemias; Glomerular Filtration Rate

MeSH Terms

Adult
Aged
Asian Continental Ancestry Group
Cholesterol/*blood
Cholesterol, HDL/*blood
Cholesterol, LDL/*blood
Cross-Sectional Studies
Female
Glomerular Filtration Rate
Humans
Male
Middle Aged
Nutrition Surveys
Odds Ratio
Predictive Value of Tests
Prevalence
Renal Insufficiency, Chronic/epidemiology/etiology/*metabolism
Republic of Korea
Risk Factors
*Severity of Illness Index
Triglycerides/*blood
Cholesterol, HDL
Cholesterol, LDL
Triglycerides
Cholesterol

Figure

• 

  Fig. 1 Prevalence of chronic kidney disease stage 3 or more according to lipid-related ratios quartile for each sex. For TG/HDL-C, the percentage of subjects with CKD stage 3 or more increased with increasing quartile group in both men and women. For TC/HDL-C, cLDL-C/HDL-C, nHDL-C/HDL-C, the percentage of subjects with CKD stage 3 or more increased with increasing quartile group only in women.

• 

  Fig. 2 Odds ratios for CKD stage 3 or more according to lipid-related ratios quartiles after adjustment for age, SBP, fasting plasma glucose, waist circumference, BMI, smoking status, alcohol-drinking status, and exercise status for each sex. In comparison with participants who were categorized in the first quartiles of each lipid-related ratio, only the fourth quartile of TG/HDL-C was associated with CKD stage 3 or more for men. For women, the fourth quartile of TC/HDL-C, the third and fourth quartile of TG/HDL-C, and the fourth quartile of nHDL-C/HDL-C were associated with CKD stage 3 or more. The ORs for CKD stage 3 or more increased with increasing quartile group for all lipid-related ratios in women.

Reference

1. Kim S, Lim CS, Han DC, Kim GS, Chin HJ, Kim SJ, Cho WY, Kim YH, Kim YS. The prevalence of chronic kidney disease and the associated factors to CKD in Urban Korea: a population-based cress-sectional epidemiologic study. J Korean Med Sci. 2009. 24:S11–S21.

2. Foley RN, Collins AJ. End-stage renal disease in the United States: an update from the United States renal data system. J Am Soc Nephrol. 2007. 18:2644–2648.

3. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca×PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001. 12:2131–2138.

4. Jungers P, Massy ZA, Nguyen Khoa T, Fumeron C, Labrunie M, Lacour B, Descamps-Latscha B, Man NK. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study. Nephrol Dial Transplant. 1997. 12:2597–2602.

5. Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. N Engl J Med. 1990. 323:1112–1119.

6. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 1994. 308:367–372.

7. Hsia SH, Pan D, Berookim P, Lee ML. A population-based, cross-sectional comparison of lipid-related indexes for symptoms of atherosclerotic disease. Am J Cardiol. 2006. 98:1047–1052.

8. Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation. 2005. 112:3375–3383.

9. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-1 and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005. 294:326–333.

10. Kang HT, Shim JY, Lee YJ, Lee JE, Linton JA, Kim JK, Lee HR. Association between the ratio of triglycerides to high-density lipoprotein cholesterol and chronic kidney disease in Korean adults: the 2005 Korean National Health and Nutrition Examination Survey. Kidney Blood Press Res. 2011. 34:173–179.

11. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001. 285:2486–2497.

12. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000. 160:459–467.

13. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002. 39:S1–S266.

14. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999. 130:461–470.

15. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972. 18:499–502.

16. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 2003. 139:802–809.

17. Fox ER, Benjamin EJ, Sarpong DF, Nagarajarao H, Taylor JK, Steffes MW, Salahudeen AK, Flessner MF, Akylbekova EL, Fox CS, et al. The relation of C-reactive protein to chronic kidney disease in African Americans: the Jackson Heart Study. BMC Nephrol. 2010. 11:1.

18. Yoon YS, Park HS, Yun KE, Kim SB. Obesity and metabolic syndrome-related chronic kidney disease in nondiabetic, nonhypertensive adults. Metabolism. 2009. 58:1737–1742.

19. Keane WF, O'Donnell MP, Kasiske BL, Kim Y. Oxidative modification of low-density lipoproteins by mesangial cells. J Am Soc Nephrol. 1993. 4:187–194.

20. Klahr S, Schreiner G, Ichikawa I. The progression of renal disease. N Engl J Med. 1988. 318:1657–1666.

21. Diamond JR, Karnovsky MJ. Focal and segmental glomerulosclerosis: analogies to atherosclerosis. Kidney Int. 1988. 33:917–924.

22. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991. 14:173–194.

23. Cusumano AM, Bodkin NL, Hansen BC, Iotti R, Owens J, Klotman PE, Kopp JB. Glomerular hypertrophy is associated with hyperinsulinemia and precedes overt diabetes in aging rhesus monkeys. Am J Kidney Dis. 2002. 40:1075–1085.

24. Kobayashi H, Tokudome G, Hara Y, Sugano N, Endo S, Suetsugu Y, Kuriyama S, Hosoya T. Insulin resistance is a risk factor for the progression of chronic kidney disease. Clin Nephrol. 2009. 71:643–651.

25. Maruyama C, Imamura K, Teramoto T. Assessment of LDL particle size by triglyceride/HDL-cholesterol ratio in non-diabetic, healthy subjects without prominent hyperlipidemia. J Atheroscler Thromb. 2003. 10:186–191.

26. Hanak V, Munoz J, Teague J, Stanley A Jr, Bittner V. Accuracy of the triglyceride to high-density lipoprotein cholesterol ratio for prediction of the low-density lipoprotein phenotype B. Am J Cardiol. 2004. 94:219–222.

27. Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent C, Buring JE, Gaziano JM. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 2003. 14:2084–2091.

28. Moorhead JF, Chan MK, El-Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet. 1982. 2:1309–1311.